Prandin® FAQ
How do PRANDIN (repaglinide) Tablets control postprandial glucosae spikes?
PRANDIN® promotes the release of insulin to respond to the post-meal rise in blood glucose.
Do patients remember to take this drug as prescribed?
Meals can act as reminders for patients to take their medication. By allowing patients to take control of their treatment schedules, PRANDIN® helps empower patients to take control of their diabetes. When they eat, they treat their condition.
What are the advantages of combining PRANDIN® with metformin?
PRANDIN® and metformin work together to control glucose levels. Because diabetes is a dual-impairment disease, it makes sense to treat it with two complementary agents such as these when monotherapy with Metformin or Prandin® does not result in adequate glycemic control.
What if a patient taking PRANDIN® misses a meal?
When patients miss a meal or change the time of a meal, they can just omit that dose or change the time of their medication to coincide with the meal.
Does PRANDIN® cause weight gain?
In clinical trials, there was no average gain in body weight when patients previously treated with oral hypoglycemic agents were switched to PRANDIN®. The average weight gain in patients treated with PRANDIN® and not previously treated with sulfonylurea drugs was 3.3%.
Has PRANDIN® been safely used in patients with renal insufficiency?
Yes. PRANDIN® may be used in patients with renal insufficiency. No initial dose adjustment is required for patients with mild to moderate renal dysfunction. Those with severe renal dysfunction should start with the 0.5-mg dose. Subsequent dosing increases should be made carefully.
What is the maximum dosage for PRANDIN®?
The recommended dose range is 0.5 mg to 4 mg taken with meals. PRANDIN® may be dosed preprandially 2, 3, or 4 times a day in response to changes in the patient's meal pattern. The maximum daily dose is 16 mg. Starting dose, dose adjustments, and maximum dose for PRANDIN® combination therapy are the same as for PRANDIN® monotherapy.
Who are appropriate candidates for PRANDIN® therapy?
Examples include patients with type 2 diabetes who are no longer controlled on diet and exercise alone, as well as patients who are no longer controlled on metformin alone and who are candidates for combination therapy.
What are the most common side effects with PRANDIN®?
The most common adverse events seen in clinical trials that resulted in a discontinuation of PRANDIN® therapy were hyperglycemia, hypoglycemia, and related symptoms. The most common other side effects reported were cold- and flu-like symptoms, headache, diarrhea, joint ache, and back pain.
|
